Critical Analysis: PROCEPT BioRobotics (NASDAQ:PRCT) vs. DIH Holding US (NASDAQ:DHAI)

DIH Holding US (NASDAQ:DHAI) and PROCEPT BioRobotics (NASDAQ:PRCT) are both business services companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Risk and Volatility

DIH Holding US has a beta of -0.57, meaning that its stock price is 157% less volatile than the S&P 500. Comparatively, PROCEPT BioRobotics has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500.

Profitability

This table compares DIH Holding US and PROCEPT BioRobotics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
DIH Holding US	N/A	-5.07%	3.35%
PROCEPT BioRobotics	-50.07%	-38.57%	-26.06%

Institutional & Insider Ownership

27.8% of DIH Holding US shares are owned by institutional investors. Comparatively, 89.5% of PROCEPT BioRobotics shares are owned by institutional investors. 49.6% of DIH Holding US shares are owned by company insiders. Comparatively, 17.4% of PROCEPT BioRobotics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares DIH Holding US and PROCEPT BioRobotics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DIH Holding US	$64.47 million	0.80	-$8.44 million	N/A	N/A
PROCEPT BioRobotics	$199.84 million	21.41	-$105.90 million	($1.95)	-42.05

DIH Holding US has higher earnings, but lower revenue than PROCEPT BioRobotics.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for DIH Holding US and PROCEPT BioRobotics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DIH Holding US	0	0	0	0	0.00
PROCEPT BioRobotics	0	1	6	0	2.86

PROCEPT BioRobotics has a consensus price target of $97.86, suggesting a potential upside of 19.34%. Given PROCEPT BioRobotics’ stronger consensus rating and higher possible upside, analysts clearly believe PROCEPT BioRobotics is more favorable than DIH Holding US.

Summary

PROCEPT BioRobotics beats DIH Holding US on 7 of the 12 factors compared between the two stocks.

About DIH Holding US

DIH Holding US, Inc. operates as a robotics and virtual reality (VR) technology provider for the rehabilitation industry in Europe, the Middle East, Africa, the United States, and the Asia Pacific. It offers ArmeoPower, a backbone robot for arm and hand therapy in an early stage of rehabilitation; ArmeoSpring for less severe patients that provides self-initiated repetitive arm and hand therapy in an extensive workspace; ArmeoSpring Pro; and Armeo Senso, for patients self-initiated and still structurally controlled movement patterns to completely open movement. The company also provides lower extremity products, including Erigo for gradual verticalization, leg mobilization, and intensive sensorimotor stimulation through cyclic leg loading; Lokomat, a robot-assisted therapy that enables training to increase the strength of muscles and a range of motion of joints in order to improve walking; Andago, a robotics smart control system that assists patients in walking naturally; C-Mill, creates a training environment; CAREN, a computer assisted rehabilitation environment; and GRAIL, an gait real-time analysis interactive lab solution for analysis training and research. In addition, it offers SafeGait, RYSEN, and M-Gait for gait and balance; and HocoNet and D-Flow software. DIH Holding US, Inc. was founded in 2021 and is based in Norwell, Massachusetts.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.